Trialsoral semaglutidebone turnovertype 2 diabetesodense university hospital

Odense trial tests oral semaglutide effect on bone turnover in type 2 diabetes

SOBER II randomizes adults aged 50 to 85 to 52 weeks of once-daily oral semaglutide or placebo, with bone marrow biopsy and microindentation endpoints.

By Priya Raman · Science Reporter

Oct 5 08:00 ETSource: ClinicalTrials.gov

The wire

01NCT06050577, a phase 2 placebo-controlled trial sponsored by Odense University Hospital, is active and no longer recruiting; it began June 2024 and runs 52 weeks of treatment.
02Bone loss is an open question for GLP-1 users, and the protocol measures bone markers, scans, bone tissue and marrow samples, plus direct bone strength by microindentation.
03The stated hypothesis is a positive effect on bone balance and strength; no results are posted, and the trial is in patients with type 2 diabetes at increased fracture risk.

From the source

The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial
NCT06050577 · PHASE2 · ACTIVE NOT RECRUITING · Sponsor: Odense University Hospital · Conditions: Type 2 Diabetes, Osteopenia.

Read at clinicaltrials.gov

Source URL https://clinicaltrials.gov/study/NCT06050577